Factors influencing concentrations of risperidone and 9‐hydroxyrisperidone in psychiatric outpatients taking immediate‐release formulations of risperidone

Abstract

AbstractObjectivesTo analyze the factors affecting the concentrations of the active moiety of risperidone (RIS) and its active metabolite 9‐hydroxyrisperidone (9‐OH‐RIS) in psychiatric outpatients taking immediate‐release formulations.MethodsThis is a retrospective study on the therapeutic drug monitoring (TDM) data regarding RIS and 9‐OH‐RIS in adult psychiatric outpatients. TDM data with simultaneous RIS and 9‐OH‐RIS monitoring from March 2018 to February 2020 and relevant medical records (including dosage, dosage form, sex, age, diagnosis, combined medication, and comorbid disease) from 399 adult psychiatric outpatients (223 males and 176 females) were included in this study.ResultsThe daily dose of RIS was 5.56 ± 2.05 mg, the concentration of total active moiety was 42.35 ± 25.46 ng/mL, and the dose‐adjusted plasma concentration (C/D) of active moiety was 7.83 ± 3.87 (ng/ml)/(mg/day). Dose, sex, and age were identified as important factors influencing concentrations of RIS and 9‐OH‐RIS in adult psychiatric outpatients.ConclusionsIndividualized medication adjustments should be made according to the specific conditions of psychiatric outpatients. The findings strongly support the use of TDM to guide dosing decisions in psychiatric outpatients taking RIS.